Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-09-01

AUTHORS

JL Byrne, C Stainer, H Hyde, G Miflin, AP Haynes, EM Bessell, NH Russell

ABSTRACT

One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Here, we report the results of 55 patients with standard risk leukaemia who have undergone allogeneic transplantation using either bone marrow (n = 48) or G-CSF mobilised peripheral blood stem cells (n = 7) using CsA and MTX for GVHD prophylaxis where the dosage of CsA was regularly adjusted to maintain a trough whole blood level of 95–205 ng/ml for the first 50 days post-transplant. To achieve this level of CsA in the immediate post-transplant period, over 40% of patients required dose adjustments of CsA as a result of sub-therapeutic levels on day +1 post-transplant. The achievement of CsA levels within the therapeutic range was expedited following the introduction of a sliding scale for dose adjustment. With this regimen we have observed a low incidence of acute GVHD with only 11% of patients developing ⩾grade II disease. With a median follow-up of 66 months (range 8–132) the probability of relapse is only 6.6%. The disease-free survival probability for all patients was 72% at 5 years. These results demonstrate that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia provided that rapid attainment of therapeutic CsA levels is achieved and maintenance within a low therapeutic range may help to maximise this effect. More... »

PAGES

541-545

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396

DOI

http://dx.doi.org/10.1038/sj.bmt.1701396

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043707730

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9758340


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Host Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Tumor Effect", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Donors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Byrne", 
        "givenName": "JL", 
        "id": "sg:person.014313340652.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014313340652.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stainer", 
        "givenName": "C", 
        "id": "sg:person.01306721446.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306721446.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hyde", 
        "givenName": "H", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miflin", 
        "givenName": "G", 
        "id": "sg:person.0644121253.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644121253.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haynes", 
        "givenName": "AP", 
        "id": "sg:person.012176706322.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012176706322.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bessell", 
        "givenName": "EM", 
        "id": "sg:person.0611001502.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611001502.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Russell", 
        "givenName": "NH", 
        "id": "sg:person.0675233407.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675233407.23"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-09-01", 
    "datePublishedReg": "1998-09-01", 
    "description": "One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Here, we report the results of 55 patients with standard risk leukaemia who have undergone allogeneic transplantation using either bone marrow (n\u2009=\u200948) or G-CSF mobilised peripheral blood stem cells (n\u2009=\u20097) using CsA and MTX for GVHD prophylaxis where the dosage of CsA was regularly adjusted to maintain a trough whole blood level of 95\u2013205\u2009ng/ml for the first 50 days post-transplant. To achieve this level of CsA in the immediate post-transplant period, over 40% of patients required dose adjustments of CsA as a result of sub-therapeutic levels on day +1 post-transplant. The achievement of CsA levels within the therapeutic range was expedited following the introduction of a sliding scale for dose adjustment. With this regimen we have observed a low incidence of acute GVHD with only 11% of patients developing \u2a7egrade II disease. With a median follow-up of 66 months (range 8\u2013132) the probability of relapse is only 6.6%. The disease-free survival probability for all patients was 72% at 5 years. These results demonstrate that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia provided that rapid attainment of therapeutic CsA levels is achieved and maintenance within a low therapeutic range may help to maximise this effect.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bmt.1701396", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "allogeneic haemopoietic stem cell transplantation", 
      "haemopoietic stem cell transplantation", 
      "stem cell transplantation", 
      "host disease", 
      "recurrent leukemia", 
      "CsA levels", 
      "cell transplantation", 
      "therapeutic range", 
      "lower incidence", 
      "trough whole blood levels", 
      "immediate post-transplant period", 
      "disease-free survival probability", 
      "peripheral blood stem cells", 
      "standard-risk leukemia", 
      "therapeutic CsA levels", 
      "post-transplant period", 
      "combination of cyclosporin", 
      "dosage of CsA", 
      "probability of relapse", 
      "blood stem cells", 
      "low therapeutic range", 
      "levels of CsA", 
      "whole blood levels", 
      "sub-therapeutic levels", 
      "GVHD suppression", 
      "GVHD prophylaxis", 
      "acute GVHD", 
      "GVHD prevention", 
      "acute graft", 
      "leukemia effect", 
      "allogeneic transplantation", 
      "dose adjustment", 
      "blood levels", 
      "high risk", 
      "patients", 
      "bone marrow", 
      "G-CSF", 
      "methotrexate", 
      "short course", 
      "transplantation", 
      "graft", 
      "leukemia", 
      "disease", 
      "CsA", 
      "prophylaxis", 
      "cyclosporin", 
      "incidence", 
      "stem cells", 
      "rapid attainment", 
      "days", 
      "survival probability", 
      "GVHD", 
      "regimens", 
      "regimen", 
      "relapse", 
      "levels", 
      "suppression", 
      "marrow", 
      "months", 
      "prevention", 
      "adjustment", 
      "risk", 
      "dosage", 
      "major aim", 
      "effect", 
      "cells", 
      "aim", 
      "effective suppression", 
      "agents", 
      "years", 
      "donors", 
      "course", 
      "period", 
      "results", 
      "loss", 
      "maintenance", 
      "combination", 
      "attainment", 
      "scale", 
      "probability", 
      "optimal usage", 
      "introduction", 
      "range", 
      "usage", 
      "achievement"
    ], 
    "name": "Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis", 
    "pagination": "541-545", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043707730"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bmt.1701396"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9758340"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bmt.1701396", 
      "https://app.dimensions.ai/details/publication/pub.1043707730"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_272.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bmt.1701396"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'


 

This table displays all metadata directly associated to this object as RDF triples.

269 TRIPLES      20 PREDICATES      130 URIs      122 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bmt.1701396 schema:about N1dde2576a1f645758eec999fd4ce82bc
2 N26210a3a1f4d4775bfbc72c84b4eb4ef
3 N2d16381b30e24df096d7d8e4b43c53c1
4 N3599753a234b4dfbb2ed9c3eef6ba886
5 N399cef5ed85a42bfbab13b3e898c8926
6 N3f8f7095c22c4f458a75164d3eb858ee
7 N46049579d2b045558a129c397279ab48
8 N5b61ec606f234e4abe4af56ab1a08a3d
9 N68f5c333644f466e8af252bead1b9190
10 N6e52366e974d4879883279f9cd2b236d
11 N79ab8391289d4138b1da3ae41de297d0
12 N7d24aa243c904473ae1ed0b95dcafe3a
13 N80d90275844d4a1abcf4061521714480
14 N868ff38920fb46f1b3f36be4518454e8
15 Na87683a9a88b4f5a91504bdd5e53adef
16 Nbeafdea4b42647be94cff9649cef8087
17 Nc6228326161c49a9bf9f3d53cea4be04
18 Ncaaf4055790249abb05c32621fa7c229
19 Ne26fafe8fe36439c802956cde7c75bc9
20 Nffcdcd9d36b446ed93dfc2c7c8c77d9e
21 anzsrc-for:11
22 anzsrc-for:1102
23 schema:author Na1f6bdee2c784260980806157c739cfc
24 schema:datePublished 1998-09-01
25 schema:datePublishedReg 1998-09-01
26 schema:description One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Here, we report the results of 55 patients with standard risk leukaemia who have undergone allogeneic transplantation using either bone marrow (n = 48) or G-CSF mobilised peripheral blood stem cells (n = 7) using CsA and MTX for GVHD prophylaxis where the dosage of CsA was regularly adjusted to maintain a trough whole blood level of 95–205 ng/ml for the first 50 days post-transplant. To achieve this level of CsA in the immediate post-transplant period, over 40% of patients required dose adjustments of CsA as a result of sub-therapeutic levels on day +1 post-transplant. The achievement of CsA levels within the therapeutic range was expedited following the introduction of a sliding scale for dose adjustment. With this regimen we have observed a low incidence of acute GVHD with only 11% of patients developing ⩾grade II disease. With a median follow-up of 66 months (range 8–132) the probability of relapse is only 6.6%. The disease-free survival probability for all patients was 72% at 5 years. These results demonstrate that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia provided that rapid attainment of therapeutic CsA levels is achieved and maintenance within a low therapeutic range may help to maximise this effect.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf Nde1ce47b9043472da844f2cb465a076c
30 Ne361b5e2d70c46d7b33073e2097a101c
31 sg:journal.1096890
32 schema:keywords CsA
33 CsA levels
34 G-CSF
35 GVHD
36 GVHD prevention
37 GVHD prophylaxis
38 GVHD suppression
39 achievement
40 acute GVHD
41 acute graft
42 adjustment
43 agents
44 aim
45 allogeneic haemopoietic stem cell transplantation
46 allogeneic transplantation
47 attainment
48 blood levels
49 blood stem cells
50 bone marrow
51 cell transplantation
52 cells
53 combination
54 combination of cyclosporin
55 course
56 cyclosporin
57 days
58 disease
59 disease-free survival probability
60 donors
61 dosage
62 dosage of CsA
63 dose adjustment
64 effect
65 effective suppression
66 graft
67 haemopoietic stem cell transplantation
68 high risk
69 host disease
70 immediate post-transplant period
71 incidence
72 introduction
73 leukemia
74 leukemia effect
75 levels
76 levels of CsA
77 loss
78 low therapeutic range
79 lower incidence
80 maintenance
81 major aim
82 marrow
83 methotrexate
84 months
85 optimal usage
86 patients
87 period
88 peripheral blood stem cells
89 post-transplant period
90 prevention
91 probability
92 probability of relapse
93 prophylaxis
94 range
95 rapid attainment
96 recurrent leukemia
97 regimen
98 regimens
99 relapse
100 results
101 risk
102 scale
103 short course
104 standard-risk leukemia
105 stem cell transplantation
106 stem cells
107 sub-therapeutic levels
108 suppression
109 survival probability
110 therapeutic CsA levels
111 therapeutic range
112 transplantation
113 trough whole blood levels
114 usage
115 whole blood levels
116 years
117 schema:name Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis
118 schema:pagination 541-545
119 schema:productId N9e9b3480a3d0453b96578c50c8789773
120 Ndfb1ddfe0c9546e59b3d19f3971e4231
121 Nff0abc2454534410bfb4be9b4d94721b
122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043707730
123 https://doi.org/10.1038/sj.bmt.1701396
124 schema:sdDatePublished 2022-12-01T06:21
125 schema:sdLicense https://scigraph.springernature.com/explorer/license/
126 schema:sdPublisher N2ac3e275520244b88d2b64a67a4d4cff
127 schema:url https://doi.org/10.1038/sj.bmt.1701396
128 sgo:license sg:explorer/license/
129 sgo:sdDataset articles
130 rdf:type schema:ScholarlyArticle
131 N014f7c6f2af04d6da607eeadca6703ac schema:affiliation grid-institutes:grid.4563.4
132 schema:familyName Hyde
133 schema:givenName H
134 rdf:type schema:Person
135 N06a8579d878347398c92c5e1da5b60b3 rdf:first sg:person.0644121253.44
136 rdf:rest Nb4fbdc7539d74681937a0db7610b45af
137 N16ea20458bda4e779428ddb17b0ba079 rdf:first sg:person.0611001502.82
138 rdf:rest N2814abb27c6e45f5a86de7364ca77e5b
139 N1dde2576a1f645758eec999fd4ce82bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Acute Disease
141 rdf:type schema:DefinedTerm
142 N26210a3a1f4d4775bfbc72c84b4eb4ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Graft vs Tumor Effect
144 rdf:type schema:DefinedTerm
145 N2814abb27c6e45f5a86de7364ca77e5b rdf:first sg:person.0675233407.23
146 rdf:rest rdf:nil
147 N2ac3e275520244b88d2b64a67a4d4cff schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 N2d16381b30e24df096d7d8e4b43c53c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Hematopoietic Stem Cell Transplantation
151 rdf:type schema:DefinedTerm
152 N3599753a234b4dfbb2ed9c3eef6ba886 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Recurrence
154 rdf:type schema:DefinedTerm
155 N399cef5ed85a42bfbab13b3e898c8926 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Cyclosporine
157 rdf:type schema:DefinedTerm
158 N3f8f7095c22c4f458a75164d3eb858ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Transplantation, Homologous
160 rdf:type schema:DefinedTerm
161 N46049579d2b045558a129c397279ab48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Adult
163 rdf:type schema:DefinedTerm
164 N5b61ec606f234e4abe4af56ab1a08a3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Leukemia
166 rdf:type schema:DefinedTerm
167 N68f5c333644f466e8af252bead1b9190 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Immunosuppressive Agents
169 rdf:type schema:DefinedTerm
170 N6e52366e974d4879883279f9cd2b236d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Middle Aged
172 rdf:type schema:DefinedTerm
173 N79ab8391289d4138b1da3ae41de297d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Female
175 rdf:type schema:DefinedTerm
176 N7d24aa243c904473ae1ed0b95dcafe3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Drug Therapy, Combination
178 rdf:type schema:DefinedTerm
179 N80d90275844d4a1abcf4061521714480 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Adolescent
181 rdf:type schema:DefinedTerm
182 N868ff38920fb46f1b3f36be4518454e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Disease-Free Survival
184 rdf:type schema:DefinedTerm
185 N9e9b3480a3d0453b96578c50c8789773 schema:name doi
186 schema:value 10.1038/sj.bmt.1701396
187 rdf:type schema:PropertyValue
188 Na1f6bdee2c784260980806157c739cfc rdf:first sg:person.014313340652.77
189 rdf:rest Nf9e0b4bd89584a188435cc507d08a84d
190 Na87683a9a88b4f5a91504bdd5e53adef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Methotrexate
192 rdf:type schema:DefinedTerm
193 Nb4fbdc7539d74681937a0db7610b45af rdf:first sg:person.012176706322.00
194 rdf:rest N16ea20458bda4e779428ddb17b0ba079
195 Nbeafdea4b42647be94cff9649cef8087 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Bone Marrow Transplantation
197 rdf:type schema:DefinedTerm
198 Nc6228326161c49a9bf9f3d53cea4be04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Humans
200 rdf:type schema:DefinedTerm
201 Ncaaf4055790249abb05c32621fa7c229 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Tissue Donors
203 rdf:type schema:DefinedTerm
204 Nd538954c70e84e799592d9749b8e32a3 rdf:first N014f7c6f2af04d6da607eeadca6703ac
205 rdf:rest N06a8579d878347398c92c5e1da5b60b3
206 Nde1ce47b9043472da844f2cb465a076c schema:volumeNumber 22
207 rdf:type schema:PublicationVolume
208 Ndfb1ddfe0c9546e59b3d19f3971e4231 schema:name pubmed_id
209 schema:value 9758340
210 rdf:type schema:PropertyValue
211 Ne26fafe8fe36439c802956cde7c75bc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Graft vs Host Disease
213 rdf:type schema:DefinedTerm
214 Ne361b5e2d70c46d7b33073e2097a101c schema:issueNumber 6
215 rdf:type schema:PublicationIssue
216 Nf9e0b4bd89584a188435cc507d08a84d rdf:first sg:person.01306721446.32
217 rdf:rest Nd538954c70e84e799592d9749b8e32a3
218 Nff0abc2454534410bfb4be9b4d94721b schema:name dimensions_id
219 schema:value pub.1043707730
220 rdf:type schema:PropertyValue
221 Nffcdcd9d36b446ed93dfc2c7c8c77d9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Male
223 rdf:type schema:DefinedTerm
224 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
225 schema:name Medical and Health Sciences
226 rdf:type schema:DefinedTerm
227 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
228 schema:name Cardiorespiratory Medicine and Haematology
229 rdf:type schema:DefinedTerm
230 sg:journal.1096890 schema:issn 0268-3369
231 1476-5365
232 schema:name Bone Marrow Transplantation
233 schema:publisher Springer Nature
234 rdf:type schema:Periodical
235 sg:person.012176706322.00 schema:affiliation grid-institutes:grid.4563.4
236 schema:familyName Haynes
237 schema:givenName AP
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012176706322.00
239 rdf:type schema:Person
240 sg:person.01306721446.32 schema:affiliation grid-institutes:grid.4563.4
241 schema:familyName Stainer
242 schema:givenName C
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306721446.32
244 rdf:type schema:Person
245 sg:person.014313340652.77 schema:affiliation grid-institutes:grid.4563.4
246 schema:familyName Byrne
247 schema:givenName JL
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014313340652.77
249 rdf:type schema:Person
250 sg:person.0611001502.82 schema:affiliation grid-institutes:grid.4563.4
251 schema:familyName Bessell
252 schema:givenName EM
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611001502.82
254 rdf:type schema:Person
255 sg:person.0644121253.44 schema:affiliation grid-institutes:grid.4563.4
256 schema:familyName Miflin
257 schema:givenName G
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644121253.44
259 rdf:type schema:Person
260 sg:person.0675233407.23 schema:affiliation grid-institutes:grid.4563.4
261 schema:familyName Russell
262 schema:givenName NH
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675233407.23
264 rdf:type schema:Person
265 grid-institutes:grid.4563.4 schema:alternateName Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
266 Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
267 schema:name Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
268 Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
269 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...